The directors present their annual report and financial statements for the year ended 31 December 2024.

The principal activity of the company since 2021 has been consultancy work, providing expert academic input to projects relating to scientific research. These include, but are not limited to, projects involving communicating outcomes from research studies and improving the quality of new scientific research studies.

Review of activities

Throughout 2024, consultancy tasks were carried out in response to spontaneous requests for HRE services, rather than HRE actively seeking new projects. This was due to an awareness of the limited personnel time available for such high-level tasks. Turnover was low, as expected, reflecting prioritisation of the particularly intensive workload of HRE’s parent company (Homeopathy Research Institute) during this reporting period.

Loan waiver from parent company:

During the year, the parent company, Homeopathy Research Institute, resolved an historical intercompany balance with Homeopathy Research Enterprises Ltd, by writing off the outstanding balance (see Note 6). This accounting treatment, approved by the Trustees and based on professional advice, better reflects the economic reality of the group structure and does not affect the consolidated position.

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

For the financial year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

Homeopathy Research Enterprises Ltd is a private company limited by shares incorporated in England and Wales. The registered office is International House, 142 Cromwell Road, Kensington, London, SW7 4EF.

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future due to the continued support of the parent company, Homeopathy Research Institute. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes.

Revenue from contracts for the provision of professional services is recognised when the provision of the service is complete.

Income from grants receivable is recognised in the period to which the grant is related.

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

The average monthly number of persons (including directors) employed by the company during the year was:

During the year, the parent company, formally resolved an historical intercompany balance with Homeopathy Research Enterprises Ltd (HRE), by writing off the outstanding amount. This action followed professional accounting advice and a comprehensive internal review of the subsidiary’s financial position.

The decision was approved by the Board of Trustees at its meeting on 24 October 2024 and reflects the practical realities of the group structure and the current role of HRE in supporting the Charity’s broader mission. As the parent charity retains full control of HRE, the write-off is accounted for as a loan waiver from its parent company and does not impact the consolidated financial position of the organisation.

This treatment ensures the balance sheet more accurately reflects the economic substance of the relationship between the Charity and its subsidiary. The Trustees consider this an appropriate step in line with good financial governance and transparency.

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

The company is a wholly owned subsidiary of Homeopathy Research Institute, a company incorporated in the UK and who's registered office is International House,142 Cromwell Road, Kensington, London SW7 4EF.